Compare · IMRN vs LLY
IMRN vs LLY
Side-by-side comparison of Immuron Limited (IMRN) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMRN and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 127120.1x IMRN ($8.4M).
- Over the past year, IMRN is down 31.3% and LLY is up 50.6% - LLY leads by 81.9 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 1 for IMRN).
- LLY has more recent analyst coverage (25 ratings vs 0 for IMRN).
- Company
- Immuron Limited
- Eli Lilly and Company
- Price
- $1.21-7.66%
- $1166.75+3.00%
- Market cap
- $8.4M
- $1.07T
- 1M return
- +41.78%
- +19.45%
- 1Y return
- -31.34%
- +50.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 1
- 16
- Recent ratings
- 0
- 25
Immuron Limited
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest IMRN
- SEC Form 6-K filed by Immuron Limited
- New insider Palumbo Flavio claimed ownership of 1,142,909 units of Ordinary Shares (SEC Form 3)
- New insider Pollock Daniel Jude claimed ownership of 743,230 units of Ordinary Shares (SEC Form 3)
- SEC Form 6-K filed by Immuron Limited
- Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream
- Presenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live stream
- SEC Form 3 filed by new insider Brennan Paul Gerard
- SEC Form 6-K filed by Immuron Limited
- New insider Kanellos Jerry claimed ownership of 333,000 units of Ordinary Shares (SEC Form 3)
- New insider Lydeamore Steven George claimed ownership of 3,155,047 units of Ordinary Shares (SEC Form 3)
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial